No Data
No Data
Blueprint Medicines Is Maintained at Buy by Needham
Needham Maintains Buy on Blueprint Medicines, Lowers Price Target to $130
Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Cuts Target Price to $130
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Earnings Preview: BPMC to Report Financial Results Pre-market on May 01
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025